AbbVie announced data from the SURVEYOR studies of its
investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and
ABT-530, an NS5A inhibitor, that show high rates of sustained virologic
response at 12 weeks post-treatment (SVR12) in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. After 12 weeks of treatment, SVR12
rates achieved were 97-100 percent in genotype 1 (GT1), 96-100 percent
in genotype 2 (GT2) and 83-94 percent in genotype 3 (GT3) patients.These data are being presented at The Liver Meeting® 2015, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
Separately, in a late-breaking presentation of the SURVEYOR-I study,
data show non-cirrhotic GT1 chronic HCV patients who received a shorter
duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved a
SVR12 rate of 97 percent.
SURVEYOR-I and SURVEYOR-II are ongoing Phase 2 clinical studies that
evaluate the safety and efficacy of ABT-493 and ABT-530, with or without
ribavirin (RBV), for 8 to 12 weeks. These data presented at AASLD
include non-cirrhotic patients with GT1, GT2 and GT3 chronic HCV
infection. Data in additional patient populations (genotypes 4-6) will
be presented at future meetings.
